Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 11/20 | 0.81 |
| ▸ | CCND1 | P24385 | 11/20 | 0.81 |
| ▸ | CDK2 | P24941 | 16/20 | 0.61 |
| ▸ | CCNE1 | P24864 | 13/20 | 0.61 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.60 |
| ▸ | CCND3 | P30281 | 3/20 | 0.60 |
| ▸ | CDK9 | P50750 | 3/20 | 0.60 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.60 |
| ▸ | CDK7 | P50613 | 1/20 | 0.53 |
| ▸ | CCNH | P51946 | 1/20 | 0.53 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.53 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.53 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20926933 | 0.91 | CDK4 (0.67) | CDK4CCND1CDK2CCNE1CCNT1 | |
| SCHEMBL20926973 | 0.90 | CDK4 (0.80) | CDK4CCND1CDK2CCNE1CCND3 | |
| SCHEMBL15249233 | 0.90 | CDK4 (1.00) | CDK4CCND1CDK2CCNE1CCNT1 | |
| SCHEMBL20926981 | 0.83 | CDK2 (0.67) | CDK4CCND1CDK2CCNE1CCNT1 | |
| SCHEMBL27272867 | 0.83 | CDK4 (0.86) | CDK4CCND1CDK2CCNE1CCNT1 | |
| SCHEMBL20926999 | 0.81 | CDK4 (0.69) | CDK4CCND1CDK2CCNE1CCNT1 | |
| SCHEMBL20842272 | 0.81 | CDK4 (0.75) | CDK4CCND1CDK2CCNE1CCNT1 | |
| SCHEMBL22280184 | 0.81 | CDK2 (0.81) | CDK4CCND1CDK2CCNE1CCNT1 | |
| SCHEMBL20926924 | 0.80 | CDK4 (0.53) | CDK4CCND1CDK2CCNE1CCND3 | |
| SCHEMBL4549919 | 0.80 | CDK4 (1.00) | CDK4CCND1CDK2CCNE1CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200239486-A1 | PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER | G1 THERAPEUTICS, INC. (US) | 2020-07-30 | — | — | US | disclosed |
| US-20190119294-A1 | PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER | G1 THERAPEUTICS, INC. (US) | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119294-A1 | PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER | TYMS, TYMP, DPYD | CDK4 43/4885CCND1 132/4885CDK2 35/4885 |
| US-20200239486-A1 | PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER | TYMS, TYMP, DPYD | CDK4 43/4885CCND1 132/4885CDK2 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.